Roche and Alnylam’s Hypertension Hopeful Zilebesiran Shows Promising Results in Combination Therapy Trial

Roche and Alnylam's joint venture, focusing on the development of zilebesiran—an RNAi therapeutic targeting angiotensinogen (AGT)—has yielded positive results in a Phase 2 trial combining zilebesiran with standard hypertension medications. The study, called KARDIA-2, demonstrated statistically significant reductions in blood pressure at three months when compared to placebo and standard drugs. Zilebesiran is designed to suppress AGT, a protein involved in blood pressure regulation, and has shown potential for twice-yearly dosing, which may improve adherence to treatment. The partnership between Roche and Alnylam aims to advance zilebesiran as a best-in-disease treatment for patients with hypertension at high cardiovascular risk.